PR Newswire LEHI, Utah, Sept. 10, 2024 LEHI, Utah, Sept. 10, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and ...
PR Newswire CAMBRIDGE, Mass., Sept. 10, 2024 CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Clear Scientific, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions and diseases caused by an excess ...
PR Newswire HOUSTON, Sept. 9, 2024 – Investigator-initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Funding for study provided by NIH and BrainUp® – Trial combines WP1066 and ...
PR Newswire NEW YORK and TUSCON, Ariz., Sept. 9, 2024 NEW YORK and TUSCON, Ariz., Sept. 9, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) encouraged scientists and drug developers to use the alpha-synuclein seed ...
PR Newswire PALM SPRINGS, Calif., Sept. 6, 2024 PALM SPRINGS, Calif., Sept. 6, 2024 /PRNewswire/ -- Leading physicians and researchers will present results from 21 clinical trials from Sunday, November 3, to Tuesday, November 5, at the ...
PR Newswire JUPITER, Fla., Sept. 6, 2024 Top-line results from Phase 1 study expected in second quarter of 2025 JUPITER, Fla., Sept. 6, 2024 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing biologic ...
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 ( Study Record | ClinicalTrials.gov ), an investigational antibody ...
PR Newswire AMSTERDAM, Sept. 4, 2024 AMSTERDAM, Sept. 4, 2024 /PRNewswire/ -- myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with the CureLGMD2i ...
PR Newswire NEW YORK, Sept. 4, 2024 NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has introduced its all-encompassing contract ...
PR Newswire SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY ...
Vanderbilt’s Phase I trial of VU319 demonstrates promising results for Alzheimer’s and schizophrenia
Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with undetectable MRD.
Hypovolemic phlebotomy, removing 10% of blood before liver surgery, can cut transfusion needs by 50%, offering a safe, cost-effective way to reduce surgery risks.
Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, suggesting lasting clinical benefits.
Discover how FarrSight ®-Twin technology utilizes digital twins to revolutionize cancer clinical trials by simulating patient responses.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers